{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T06:10:23Z","timestamp":1778566223297,"version":"3.51.4"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":43,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004329","name":"The Slovenian Research and Innovation Agency","doi-asserted-by":"publisher","award":["P1-0245, J3-4504, NC-25002, N3-0394, young researcher grant to AH"],"award-info":[{"award-number":["P1-0245, J3-4504, NC-25002, N3-0394, young researcher grant to AH"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004329","name":"The Slovenian Research and Innovation Agency","doi-asserted-by":"publisher","award":["P1-0245, J3-4504, NC-25002, N3-0394"],"award-info":[{"award-number":["P1-0245, J3-4504, NC-25002, N3-0394"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004329","name":"The Slovenian Research and Innovation Agency","doi-asserted-by":"publisher","award":["P1-0245, J3-4504, NC-25002, N3-0394"],"award-info":[{"award-number":["P1-0245, J3-4504, NC-25002, N3-0394"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004329","name":"The Slovenian Research and Innovation Agency","doi-asserted-by":"publisher","award":["P1-0245, J3-4504, NC-25002, N3-0394"],"award-info":[{"award-number":["P1-0245, J3-4504, NC-25002, N3-0394"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004329","name":"The Slovenian Research and Innovation Agency","doi-asserted-by":"publisher","award":["P1-0245, J3-4504, NC-25002, N3-0394"],"award-info":[{"award-number":["P1-0245, J3-4504, NC-25002, N3-0394"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004329","name":"The Slovenian Research and Innovation Agency","doi-asserted-by":"publisher","award":["P1-0245, J3-4504, NC-25002, N3-0394"],"award-info":[{"award-number":["P1-0245, J3-4504, NC-25002, N3-0394"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004329","name":"The Slovenian Research and Innovation Agency","doi-asserted-by":"publisher","award":["P1-0245, J3-4504, NC-25002, N3-0394"],"award-info":[{"award-number":["P1-0245, J3-4504, NC-25002, N3-0394"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012329","name":"European Association of National Metrology Institutes","doi-asserted-by":"publisher","award":["GenomeMET 22HLT06"],"award-info":[{"award-number":["GenomeMET 22HLT06"]}],"id":[{"id":"10.13039\/100012329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018693","name":"HORIZON EUROPE Framework Programme","doi-asserted-by":"publisher","award":["CutCancer 101079113, SPACETIME 101136552, UNCAN-CONNECT 101215206"],"award-info":[{"award-number":["CutCancer 101079113, SPACETIME 101136552, UNCAN-CONNECT 101215206"]}],"id":[{"id":"10.13039\/100018693","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Commun Signal"],"DOI":"10.1186\/s12964-026-02826-y","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T05:54:57Z","timestamp":1774850097000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Glioblastoma\u2013natural killer cell crosstalk: insights from dynamic spheroid models reveal the importance of secreted cytokines and the CD155 axis"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6373-7603","authenticated-orcid":false,"given":"Anamarija","family":"Habi\u010d","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tina","family":"Kolenc Milavec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pia","family":"\u017di\u017eek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u0160pela","family":"Kladnik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernarda","family":"Majc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuela","family":"Senjor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milica","family":"Peri\u0161i\u0107 Nanut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrej","family":"Por\u010dnik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Borut","family":"Prestor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Urban","family":"\u0160vajger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3041-1156","authenticated-orcid":false,"given":"Metka","family":"Novak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0247-5811","authenticated-orcid":false,"given":"Barbara","family":"Breznik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,30]]},"reference":[{"issue":"10412","key":"2826_CR1","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1016\/S0140-6736(23)01054-1","volume":"402","author":"MJ van den Bent","year":"2023","unstructured":"van den Bent MJ, Geurts M, French PJ, Smits M, Capper D, Bromberg JEC, et al. Primary brain tumours in adults. Lancet. 2023;402(10412):1564\u201379.","journal-title":"Lancet"},{"issue":"5","key":"2826_CR2","first-page":"381","volume":"71","author":"KD Miller","year":"2021","unstructured":"Miller KD, Ostrom QT, Kruchko C, Patil N, Tihan T, Cioffi G, et al. Brain and other central nervous system tumor statistics, 2021. CA Cancer J Clin. 2021;71(5):381\u2013406.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"2826_CR3","first-page":"1","volume":"8","author":"L Tang","year":"2023","unstructured":"Tang L, Huang Z, Mei H, Hu Y. Immunotherapy in hematologic malignancies: achievements, challenges and future prospects. Signal Transduct Target Ther. 2023;8(1):1\u201339.","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"2826_CR4","doi-asserted-by":"publisher","first-page":"655","DOI":"10.3390\/biomedicines10030655","volume":"10","author":"P Guha","year":"2022","unstructured":"Guha P, Heatherton KR, O\u2019connell KP, Alexander IS, Katz SC. Assessing the future of solid tumor immunotherapy. Biomedicines. 2022;10(3):655.","journal-title":"Biomedicines"},{"issue":"12","key":"2826_CR5","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1038\/s41423-024-01226-x","volume":"21","author":"Y Liu","year":"2024","unstructured":"Liu Y, Zhou F, Ali H, Lathia JD, Chen P. Immunotherapy for glioblastoma: current state, challenges, and future perspectives. Cell Mol Immunol. 2024;21(12):1354\u201375.","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"2826_CR6","doi-asserted-by":"publisher","first-page":"188458","DOI":"10.1016\/j.bbcan.2020.188458","volume":"1875","author":"F Akter","year":"2020","unstructured":"Akter F, Simon B, de Boer NL, Redjal N, Wakimoto H, Shah K. Pre-clinical tumor models of primary brain tumors: challenges and opportunities. Biochim Biophys acta Rev cancer. 2020;1875(1):188458.","journal-title":"Biochim Biophys acta Rev cancer"},{"issue":"2","key":"2826_CR7","doi-asserted-by":"publisher","first-page":"265","DOI":"10.3390\/cells10020265","volume":"10","author":"B Majc","year":"2021","unstructured":"Majc B, Novak M, Jerala NK, Jewett A, Breznik B. Immunotherapy of glioblastoma: current strategies and challenges in tumor model development. Cells. 2021;10(2):265.","journal-title":"Cells"},{"issue":"1","key":"2826_CR8","first-page":"1","volume":"11","author":"Q Wang","year":"2025","unstructured":"Wang Q, Yuan F, Zuo X, Li M. Breakthroughs and challenges of organoid models for assessing cancer immunotherapy: a cutting-edge tool for advancing personalised treatments. Cell Death Discov. 2025;11(1):1\u201313.","journal-title":"Cell Death Discov"},{"issue":"1","key":"2826_CR9","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3390\/cancers13010019","volume":"13","author":"R Wouters","year":"2021","unstructured":"Wouters R, Bevers S, Riva M, De Smet F, Coosemans A. Immunocompetent mouse models in the search for effective immunotherapy in glioblastoma. Cancers. 2021;13(1):19.","journal-title":"Cancers"},{"issue":"12","key":"2826_CR10","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1039\/D0LC01305F","volume":"21","author":"K Paterson","year":"2021","unstructured":"Paterson K, Zanivan S, Glasspool R, Coffelt SB, Zagnoni M. Microfluidic technologies for immunotherapy studies on solid tumours. Lab Chip. 2021;21(12):2306.","journal-title":"Lab Chip"},{"issue":"2","key":"2826_CR11","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/s41577-022-00732-1","volume":"23","author":"NK Wolf","year":"2022","unstructured":"Wolf NK, Kissiov DU, Raulet DH. Roles of natural killer cells in immunity to cancer, and applications to immunotherapy. Nat Rev Immunol. 2022;23(2):90\u2013105.","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"2826_CR12","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41423-019-0206-4","volume":"16","author":"S Sivori","year":"2019","unstructured":"Sivori S, Vacca P, Del Zotto G, Munari E, Mingari MC, Moretta L. Human NK cells: surface receptors, inhibitory checkpoints, and translational applications. Cell Mol Immunol. 2019;16(5):430.","journal-title":"Cell Mol Immunol"},{"issue":"6","key":"2826_CR13","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1002\/JLB.MR0718-269R","volume":"105","author":"I Prager","year":"2019","unstructured":"Prager I, Watzl C. Mechanisms of natural killer cell-mediated cellular cytotoxicity. J Leukoc Biol. 2019;105(6):1319\u201329.","journal-title":"J Leukoc Biol"},{"key":"2826_CR14","doi-asserted-by":"publisher","first-page":"896228","DOI":"10.3389\/fimmu.2022.896228","volume":"13","author":"A Ram\u00edrez-Labrada","year":"2022","unstructured":"Ram\u00edrez-Labrada A, Pesini C, Santiago L, Hidalgo S, Calvo-P\u00e9rez A, O\u00f1ate C, et al. All About (NK Cell-Mediated) death in two acts and an unexpected encore: initiation, execution and activation of adaptive immunity. Front Immunol. 2022;13:896228.","journal-title":"Front Immunol"},{"issue":"4","key":"2826_CR15","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/icb.2017.6","volume":"95","author":"MC Ochoa","year":"2017","unstructured":"Ochoa MC, Minute L, Rodriguez I, Garasa S, Perez-Ruiz E, Inog\u00e9s S, et al. Antibody-dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells. Immunol Cell Biol. 2017;95(4):347\u201355.","journal-title":"Immunol Cell Biol"},{"key":"2826_CR16","doi-asserted-by":"crossref","unstructured":"Kilian M, Friedrich MJ, Hai-Ning Lu K, Vonh\u00f6ren D, Jansky S, Michel J, et al. The immunoglobulin superfamily ligand B7H6 subjects T cell responses to NK cell surveillance. Sci Immunol. 2024;9(95):eadj7970.","DOI":"10.1126\/sciimmunol.adj7970"},{"issue":"7463","key":"2826_CR17","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nature12477","volume":"500","author":"LB Alexandrov","year":"2013","unstructured":"Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SAJR, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. Nature. 2013;500(7463):415\u201321.","journal-title":"Nature"},{"issue":"1","key":"2826_CR18","first-page":"1","volume":"7","author":"J Fares","year":"2023","unstructured":"Fares J, Davis ZB, Rechberger JS, Toll SA, Schwartz JD, Daniels DJ, et al. Advances in NK cell therapy for brain tumors. npj Precis Oncol. 2023;7(1):1\u201317.","journal-title":"npj Precis Oncol"},{"issue":"3","key":"2826_CR19","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.3390\/ijms24032111","volume":"24","author":"T Morimoto","year":"2023","unstructured":"Morimoto T, Nakazawa T, Maeoka R, Nakagawa I, Tsujimura T, Matsuda R. Natural killer cell-based immunotherapy against glioblastoma. Int J Mol Sci. 2023;24(3):2111.","journal-title":"Int J Mol Sci"},{"key":"2826_CR20","doi-asserted-by":"crossref","unstructured":"Breznik B, Ko MW, Tse C, Chen PC, Senjor E, Majc B, et al. Infiltrating natural killer cells bind, lyse and increase chemotherapy efficacy in glioblastoma stem-like tumorospheres. Commun Biol. 2022;5(1):436.","DOI":"10.1038\/s42003-022-03402-z"},{"issue":"6","key":"2826_CR21","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1016\/j.ymthe.2025.02.043","volume":"33","author":"P Poorva","year":"2025","unstructured":"Poorva P, Mast J, Cao B, Shah MV, Pollok KE, Shen J. Killing the killers: Natural killer cell therapy targeting glioma stem cells in high-grade glioma. Mol Ther. 2025;33(6):2462\u201378.","journal-title":"Mol Ther"},{"issue":"2","key":"2826_CR22","doi-asserted-by":"publisher","first-page":"400","DOI":"10.3390\/biomedicines10020400","volume":"10","author":"LHR da Silva","year":"2022","unstructured":"da Silva LHR, Catharino LCC, da Silva VJ, Evangelista GCM, Barbuto JAM. The war is on: the immune system against glioblastoma\u2014how can NK cells drive this battle? Biomedicines. 2022;10(2):400.","journal-title":"Biomedicines"},{"issue":"7","key":"2826_CR23","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1016\/j.cell.2020.04.055","volume":"181","author":"E Friebel","year":"2020","unstructured":"Friebel E, Kapolou K, Unger S, N\u00fa\u00f1ez NG, Utz S, Rushing EJ, et al. Single-cell mapping of human brain cancer reveals tumor-specific instruction of tissue-invading leukocytes. Cell. 2020;181(7):1626\u20131642.e20.","journal-title":"Cell"},{"issue":"7","key":"2826_CR24","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1016\/j.cell.2020.05.007","volume":"181","author":"F Klemm","year":"2020","unstructured":"Klemm F, Maas RR, Bowman RL, Kornete M, Soukup K, Nassiri S, et al. Interrogation of the microenvironmental landscape in brain tumors reveals disease-specific alterations of immune cells. Cell. 2020;181(7):1643\u20131660.e17.","journal-title":"Cell"},{"key":"2826_CR25","doi-asserted-by":"crossref","unstructured":"Zhong QY, Fan EX, Feng GY, Chen QY, Gou XX, Yue GJ, et al. A gene expression-based study on immune cell subtypes and glioma prognosis. BMC Cancer. 2019;19(1):1116.","DOI":"10.1186\/s12885-019-6324-7"},{"issue":"1","key":"2826_CR26","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1093\/neuonc\/nop009","volume":"12","author":"CA Crane","year":"2010","unstructured":"Crane CA, Han SJ, Barry JJ, Ahn BJ, Lanier LL, Parsa AT. TGF-beta downregulates the activating receptor NKG2D on NK cells and CD8\u2009+\u2009T cells in glioma patients. Neuro Oncol. 2010;12(1):7\u201313.","journal-title":"Neuro Oncol"},{"issue":"20","key":"2826_CR27","doi-asserted-by":"publisher","first-page":"7596","DOI":"10.1158\/0008-5472.CAN-04-1627","volume":"64","author":"MA Friese","year":"2004","unstructured":"Friese MA, Wischhusen J, Wick W, Weiler M, Eisele G, Steinle A, et al. RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo. Cancer Res. 2004;64(20):7596\u2013603.","journal-title":"Cancer Res"},{"issue":"14","key":"2826_CR28","doi-asserted-by":"publisher","first-page":"e142116","DOI":"10.1172\/JCI142116","volume":"131","author":"H Shaim","year":"2021","unstructured":"Shaim H, Shanley M, Basar R, Daher M, Gumin J, Zamler DB, et al. Targeting the \u03b1v integrin\/TGF-\u03b2 axis improves natural killer cell function against glioblastoma stem cells. J Clin Invest. 2021;131(14):e142116.","journal-title":"J Clin Invest"},{"issue":"23","key":"2826_CR29","doi-asserted-by":"publisher","first-page":"6514","DOI":"10.1158\/1078-0432.CCR-21-1392","volume":"27","author":"L Zhai","year":"2021","unstructured":"Zhai L, Bell A, Ladomersky E, Lauing KL, Bollu L, Nguyen B, et al. Tumor cell IDO enhances immune suppression and decreases survival independent of tryptophan metabolism in glioblastoma. Clin Cancer Res. 2021;27(23):6514.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2826_CR30","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1007\/s12032-022-01724-w","volume":"39","author":"H Hosseinalizadeh","year":"2022","unstructured":"Hosseinalizadeh H, Mahmoodpour M, Samadani AA, Roudkenar MH. The immunosuppressive role of indoleamine 2, 3-dioxygenase in glioblastoma: mechanism of action and immunotherapeutic strategies. Med Oncol. 2022;39(9):130.","journal-title":"Med Oncol"},{"issue":"1","key":"2826_CR31","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1186\/s13046-019-1310-0","volume":"38","author":"J Wu","year":"2019","unstructured":"Wu J, Gao FX, Wang C, Qin M, Han F, Xu T, et al. IL-6 and IL-8 secreted by tumour cells impair the function of NK cells via the STAT3 pathway in oesophageal squamous cell carcinoma. J Exp Clin Cancer Res. 2019;38(1):321.","journal-title":"J Exp Clin Cancer Res"},{"issue":"2","key":"2826_CR32","doi-asserted-by":"publisher","first-page":"138","DOI":"10.21147\/j.issn.1000-9604.2024.02.04","volume":"36","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Guo F, Wang Y. Hypoxic tumor microenvironment: destroyer of natural killer cell function. Chin J Cancer Res. 2024;36(2):138.","journal-title":"Chin J Cancer Res"},{"issue":"7","key":"2826_CR33","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nmeth.2019","volume":"9","author":"J Schindelin","year":"2012","unstructured":"Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, et al. Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012;9(7):676\u201382.","journal-title":"Nat Methods"},{"key":"2826_CR34","doi-asserted-by":"publisher","first-page":"1471012","DOI":"10.3389\/fbioe.2024.1471012","volume":"12","author":"C Bach","year":"2024","unstructured":"Bach C, Glasow A, Baran-Schmidt R, Oppermann H, Bach C, Meixensberger J, et al. Rapid and reproducible generation of glioblastoma spheroids for high-throughput drug screening. Front Bioeng Biotechnol. 2024;12:1471012.","journal-title":"Front Bioeng Biotechnol"},{"issue":"24","key":"2826_CR35","doi-asserted-by":"publisher","first-page":"6635","DOI":"10.1039\/D5LC00249D","volume":"25","author":"X Mousset","year":"2025","unstructured":"Mousset X, Kuermanbayi S, Dupuis C, Jeger-Madiot N, Delaunay V, Ibdaih A, et al. Immune cell infiltration of patient derived glioblastoma cell spheroids in acoustic levitation in bulk acoustic wave devices. Lab Chip. 2025;25(24):6635\u201349.","journal-title":"Lab Chip"},{"key":"2826_CR36","doi-asserted-by":"crossref","unstructured":"Zhu G, Shi X, Jiang Y, Zhang W, Guo L, Pei G et al. Microgravity-cultured glioblastoma organoids integrated with microfluidic chip for CAR-\u03b3\u03b4 T evaluation. Commun Biol 2025 81. 2025;8(1):1791.","DOI":"10.1038\/s42003-025-09390-0"},{"key":"2826_CR37","doi-asserted-by":"publisher","first-page":"106033","DOI":"10.1016\/j.jddst.2024.106033","volume":"100","author":"S Arora","year":"2024","unstructured":"Arora S, Singh S, Mittal A, Desai N, Khatri DK, Gugulothu D, et al. Spheroids in cancer research: recent advances and opportunities. J Drug Deliv Sci Technol. 2024;100:106033.","journal-title":"J Drug Deliv Sci Technol"},{"issue":"7","key":"2826_CR38","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1093\/jnen\/nlab044","volume":"80","author":"M Prosniak","year":"2021","unstructured":"Prosniak M, Kenyon LC, Hooper DC. Glioblastoma contains topologically distinct proliferative and metabolically defined subpopulations of Nestin- and Glut1-expressing cells. J Neuropathol Exp Neurol. 2021;80(7):674\u201384.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"3","key":"2826_CR39","first-page":"139","volume":"8","author":"L Annovazzi","year":"2011","unstructured":"Annovazzi L, Mellai M, Caldera V, Valente G, Schiffer D. SOX2 expression and amplification in gliomas and glioma cell lines. Cancer Genomics Proteom. 2011;8(3):139\u201347.","journal-title":"Cancer Genomics Proteom"},{"issue":"11","key":"2826_CR40","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1093\/neuonc\/nos216","volume":"14","author":"MA Proescholdt","year":"2012","unstructured":"Proescholdt MA, Merrill MJ, Stoerr EM, Lohmeier A, Pohl F, Brawanski A. Function of carbonic anhydrase IX in glioblastoma multiforme. Neuro Oncol. 2012;14(11):1357.","journal-title":"Neuro Oncol"},{"key":"2826_CR41","doi-asserted-by":"publisher","first-page":"924775","DOI":"10.3389\/fimmu.2022.924775","volume":"13","author":"I Garc\u00e9s-L\u00e1zaro","year":"2022","unstructured":"Garc\u00e9s-L\u00e1zaro I, Kotzur R, Cerwenka A, Mandelboim O. NK cells under hypoxia: the two faces of vascularization in tumor and pregnancy. Front Immunol. 2022;13:924775.","journal-title":"Front Immunol"},{"issue":"4","key":"2826_CR42","doi-asserted-by":"publisher","first-page":"992","DOI":"10.3390\/cells9040992","volume":"9","author":"A Vito","year":"2020","unstructured":"Vito A, El-Sayes N, Mossman K. Hypoxia-driven immune escape in the tumor microenvironment. Cells. 2020;9(4):992.","journal-title":"Cells"},{"issue":"3","key":"2826_CR43","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.ccell.2023.01.009","volume":"41","author":"EN Arner","year":"2023","unstructured":"Arner EN, Rathmell JC. Metabolic programming and immune suppression in the tumor microenvironment. Cancer Cell. 2023;41(3):421.","journal-title":"Cancer Cell"},{"issue":"9","key":"2826_CR44","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.chembiol.2023.08.011","volume":"30","author":"GP Lobel","year":"2023","unstructured":"Lobel GP, Jiang Y, Simon MC. Tumor microenvironmental nutrients, cellular responses, and cancer. Cell Chem Biol. 2023;30(9):1015\u201332.","journal-title":"Cell Chem Biol"},{"key":"2826_CR45","doi-asserted-by":"publisher","first-page":"603640","DOI":"10.3389\/fimmu.2020.603640","volume":"11","author":"N Boucherit","year":"2020","unstructured":"Boucherit N, Gorvel L, Olive D. 3D tumor models and their use for the testing of immunotherapies. Front Immunol. 2020;11:603640.","journal-title":"Front Immunol"},{"issue":"5","key":"2826_CR46","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1021\/pr500064m","volume":"13","author":"W He","year":"2014","unstructured":"He W, He W, Kuang Y, Xing X, Simpson RJ, Huang H, et al. Proteomic comparison of 3D and 2D glioma models reveals increased HLA-E expression in 3D models is associated with resistance to NK cell-mediated cytotoxicity. J Proteome Res. 2014;13(5):2272\u201381.","journal-title":"J Proteome Res"},{"key":"2826_CR47","doi-asserted-by":"crossref","unstructured":"Braun FK, Rothhammer-Hampl T, Lorenz J, Pohl S, Menevse AN, Vollmann-Zwerenz A, et al. Scaffold-Based (Matrigel\u2122) 3D culture technique of glioblastoma recovers a patient-like immunosuppressive phenotype. Cells. 2023;12(14):1856.","DOI":"10.3390\/cells12141856"},{"issue":"3","key":"2826_CR48","doi-asserted-by":"publisher","first-page":"236","DOI":"10.3390\/ph14030236","volume":"14","author":"T Burster","year":"2021","unstructured":"Burster T, G\u00e4rtner F, Bulach C, Zhanapiya A, Gihring A, Knippschild U. Regulation of MHC I molecules in glioblastoma cells and the sensitizing of NK cells. Pharmaceuticals. 2021;14(3):236.","journal-title":"Pharmaceuticals"},{"issue":"19","key":"2826_CR49","doi-asserted-by":"publisher","first-page":"4896","DOI":"10.3390\/cancers13194896","volume":"13","author":"T Morimoto","year":"2021","unstructured":"Morimoto T, Nakazawa T, Matsuda R, Nishimura F, Nakamura M, Yamada S, et al. Evaluation of comprehensive gene expression and nk cellmediated killing in glioblastoma cell line-derived spheroids. Cancers (Basel). 2021;13(19):4896.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"2826_CR50","doi-asserted-by":"publisher","first-page":"e24808","DOI":"10.1016\/j.heliyon.2024.e24808","volume":"10","author":"MA Heinrich","year":"2024","unstructured":"Heinrich MA, Huynh NT, Heinrich L, Prakash J. Understanding glioblastoma stromal barriers against NK cell attack using tri-culture 3D spheroid model. Heliyon. 2024;10(3):e24808.","journal-title":"Heliyon"},{"issue":"1","key":"2826_CR51","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s40478-025-01984-3","volume":"13","author":"B Meehan","year":"2025","unstructured":"Meehan B, Adnani L, Zhu X, Tawil N, Garnier D, Nakano I, et al. Curative timed NK cell-based immunochemotherapy aborts brain tumour recurrence driven by mesenchymal glioma stem cells. Acta Neuropathol Commun. 2025;13(1):64.","journal-title":"Acta Neuropathol Commun"},{"issue":"22","key":"2826_CR52","doi-asserted-by":"publisher","first-page":"14164","DOI":"10.3390\/ijms232214164","volume":"23","author":"LD Robilliard","year":"2022","unstructured":"Robilliard LD, Yu J, Anchan A, Finlay G, Angel CE, Graham ES. Comprehensive assessment of secreted immuno-modulatory cytokines by serum-differentiated and stem-like glioblastoma cells reveals distinct differences between glioblastoma phenotypes. Int J Mol Sci. 2022;23(22):14164.","journal-title":"Int J Mol Sci"},{"issue":"19","key":"2826_CR53","doi-asserted-by":"publisher","first-page":"5671","DOI":"10.1158\/0008-5472.CAN-16-0144","volume":"76","author":"AL Chang","year":"2016","unstructured":"Chang AL, Miska J, Wainwright DA, Dey M, Rivetta CV, Yu D, et al. CCL2 produced by the glioma microenvironment is essential for the recruitment of regulatory t cells and myeloid-derived suppressor cells. Cancer Res. 2016;76(19):5671\u201382.","journal-title":"Cancer Res"},{"key":"2826_CR54","doi-asserted-by":"publisher","first-page":"993444","DOI":"10.3389\/fimmu.2022.993444","volume":"13","author":"GP Takacs","year":"2023","unstructured":"Takacs GP, Kreiger CJ, Luo D, Tian G, Garcia JS, Deleyrolle LP, et al. Glioma-derived CCL2 and CCL7 mediate migration of immune suppressive CCR2+\/CX3CR1\u2009+\u2009M-MDSCs into the tumor microenvironment in a redundant manner. Front Immunol. 2023;13:993444.","journal-title":"Front Immunol"},{"key":"2826_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neuint.2016.12.013","volume":"103","author":"A Vakilian","year":"2017","unstructured":"Vakilian A, Khorramdelazad H, Heidari P, Sheikh Rezaei Z, Hassanshahi G. CCL2\/CCR2 signaling pathway in glioblastoma multiforme. Neurochem Int. 2017;103:1\u20137.","journal-title":"Neurochem Int"},{"issue":"15","key":"2826_CR56","doi-asserted-by":"publisher","first-page":"3924","DOI":"10.1158\/1078-0432.CCR-15-2463","volume":"22","author":"C Alfaro","year":"2016","unstructured":"Alfaro C, Teijeira A, O\u00f1ate C, Perez G, Sanmamed MF, Andueza MP, et al. Tumor-produced interleukin-8 attracts human myeloid-derived suppressor cells and elicits extrusion of neutrophil extracellular traps (NETs). Clin Cancer Res. 2016;22(15):3924\u201336.","journal-title":"Clin Cancer Res"},{"key":"2826_CR57","doi-asserted-by":"crossref","unstructured":"Jackson C, Cherry C, Bom S, Dykema AG, Wang R, Thompson E, et al. Distinct myeloid-derived suppressor cell populations in human glioblastoma. Sci (80-). 2025;387(6731):eabm5214.","DOI":"10.1126\/science.abm5214"},{"key":"2826_CR58","doi-asserted-by":"crossref","unstructured":"Weber R, Groth C, Lasser S, Arkhypov I, Petrova V, Altevogt P, et al. IL-6 as a major regulator of MDSC activity and possible target for cancer immunotherapy. Cell Immunol. 2021;359:104254.","DOI":"10.1016\/j.cellimm.2020.104254"},{"issue":"8","key":"2826_CR59","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1016\/j.ccell.2024.07.007","volume":"42","author":"M Shanley","year":"2024","unstructured":"Shanley M, Daher M, Dou J, Li S, Basar R, Rafei H, et al. Interleukin-21 engineering enhances NK cell activity against glioblastoma via CEBPD. Cancer Cell. 2024;42(8):1450\u20131466.e11.","journal-title":"Cancer Cell"},{"issue":"12","key":"2826_CR60","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1172\/JCI18125","volume":"112","author":"BE Morrison","year":"2003","unstructured":"Morrison BE, Park SJ, Mooney JM, Mehrad B. Chemokine-mediated recruitment of NK cells is a critical host defense mechanism in invasive aspergillosis. J Clin Invest. 2003;112(12):1862.","journal-title":"J Clin Invest"},{"key":"2826_CR61","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.molimm.2018.08.002","volume":"101","author":"Q He","year":"2018","unstructured":"He Q, Shi X, Zhou B, Teng J, Zhang C, Liu S, et al. Interleukin 8 (CXCL8)-CXC chemokine receptor 2 (CXCR2) axis contributes to MiR-4437-associated recruitment of granulocytes and natural killer cells in ischemic stroke. Mol Immunol. 2018;101:440\u20139.","journal-title":"Mol Immunol"},{"issue":"4","key":"2826_CR62","doi-asserted-by":"publisher","first-page":"448","DOI":"10.4161\/onci.19788","volume":"1","author":"L Vujanovic","year":"2012","unstructured":"Vujanovic L, Ballard W, Thorne SH, Vujanovic NL, Butterfield LH. Adenovirus-engineered human dendritic cells induce natural killer cell chemotaxis via CXCL8\/IL-8 and CXCL10\/IP-10. Oncoimmunology. 2012;1(4):448\u201357.","journal-title":"Oncoimmunology"},{"key":"2826_CR63","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jneuroim.2015.03.007","volume":"282","author":"E Serrano-Pertierra","year":"2015","unstructured":"Serrano-Pertierra E, Blanco-Gelaz MA, Oliva-Nacarino P, Mart\u00ednez-Camblor P, Villafani J, L\u00f3pez-Larrea C, et al. Increased natural killer cell chemotaxis to CXCL12 in patients with multiple sclerosis. J Neuroimmunol. 2015;282:39\u201344.","journal-title":"J Neuroimmunol"},{"issue":"1","key":"2826_CR64","first-page":"1","volume":"7","author":"GH Ran","year":"2022","unstructured":"Ran GH, Lin YQ, Tian L, Zhang T, Yan DM, Yu JH, et al. Natural killer cell homing and trafficking in tissues and tumors: from biology to application. Signal Transduct Target Ther. 2022;7(1):1\u201321.","journal-title":"Signal Transduct Target Ther"},{"issue":"12","key":"2826_CR65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-023-06354-2","volume":"14","author":"TYH Chan","year":"2023","unstructured":"Chan TYH, Wong JSY, Kiang KMY, Sun CWY, Leung GKK. The duality of CXCR3 in glioblastoma: unveiling autocrine and paracrine mechanisms for novel therapeutic approaches. Cell Death Dis. 2023;14(12):1\u201313.","journal-title":"Cell Death Dis"},{"issue":"2","key":"2826_CR66","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/j.1750-3639.2011.00515.x","volume":"22","author":"T Avril","year":"2012","unstructured":"Avril T, Vauleon E, Hamlat A, Saikali S, Etcheverry A, Delmas C, et al. Human glioblastoma stem-like cells are more sensitive to allogeneic NK and T cell-mediated killing compared with serum-cultured glioblastoma cells. Brain Pathol. 2012;22(2):159\u201374.","journal-title":"Brain Pathol"},{"issue":"JUN","key":"2826_CR67","first-page":"367492","volume":"9","author":"HN Haspels","year":"2018","unstructured":"Haspels HN, Rahman MA, Joseph JV, Navarro AG, Chekenya M. Glioblastoma stem-like cells are more susceptible than differentiated cells to natural killer cell lysis mediated through killer immunoglobulin-like receptors-human leukocyte antigen ligand mismatch and activation receptor-ligand interactions. Front Immunol. 2018;9(JUN):367492.","journal-title":"Front Immunol"},{"issue":"1","key":"2826_CR68","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/cei.13403","volume":"200","author":"HJ Close","year":"2020","unstructured":"Close HJ, Stead LF, Nsengimana J, Reilly KA, Droop A, Wurdak H, et al. Expression profiling of single cells and patient cohorts identifies multiple immunosuppressive pathways and an altered NK cell phenotype in glioblastoma. Clin Exp Immunol. 2020;200(1):33.","journal-title":"Clin Exp Immunol"},{"issue":"7948","key":"2826_CR69","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/s41586-022-05680-3","volume":"614","author":"E Karimi","year":"2023","unstructured":"Karimi E, Yu MW, Maritan SM, Perus LJM, Rezanejad M, Sorin M, et al. Single-cell spatial immune landscapes of primary and metastatic brain tumours. Nat. 2023;614(7948):555\u201363.","journal-title":"Nat"},{"key":"2826_CR70","doi-asserted-by":"publisher","first-page":"835","DOI":"10.3389\/fimmu.2020.00835","volume":"11","author":"W Fu","year":"2020","unstructured":"Fu W, Wang W, Li H, Jiao Y, Huo R, Yan Z, et al. Single-cell atlas reveals complexity of the immunosuppressive microenvironment of initial and recurrent glioblastoma. Front Immunol. 2020;11:835.","journal-title":"Front Immunol"},{"key":"2826_CR71","doi-asserted-by":"publisher","first-page":"6248590","DOI":"10.1155\/2018\/6248590","volume":"2018","author":"B Han","year":"2018","unstructured":"Han B, Mao FY, Zhao YL, Lv YP, Teng YS, Duan M, et al. Altered NKp30, NKp46, NKG2D, and DNAM-1 Expression on Circulating NK Cells Is Associated with Tumor Progression in Human Gastric Cancer. J Immunol Res. 2018;2018:6248590.","journal-title":"J Immunol Res"},{"issue":"5","key":"2826_CR72","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.4049\/jimmunol.1200140","volume":"190","author":"E Mamessier","year":"2013","unstructured":"Mamessier E, Pradel LC, Thibult M-L, Drevet C, Zouine A, Jacquemier J, et al. Peripheral blood NK cells from breast cancer patients are tumor-induced composite subsets. J Immunol. 2013;190(5):2424\u201336.","journal-title":"J Immunol"},{"key":"2826_CR73","doi-asserted-by":"publisher","first-page":"1708281","DOI":"10.3389\/fimmu.2025.1708281","volume":"16","author":"E Senjor","year":"2025","unstructured":"Senjor E, Habi\u010d A, \u0160vajger U, Mitrovi\u0107 A, Proj M, Por\u010dnik A, et al. Targeting cystatin F activation enhances NK cell cytotoxicity in glioblastoma models. Front Immunol. 2025;16:1708281.","journal-title":"Front Immunol"},{"issue":"3","key":"2826_CR74","doi-asserted-by":"publisher","first-page":"922","DOI":"10.3390\/ijms21030922","volume":"21","author":"R Molfetta","year":"2020","unstructured":"Molfetta R, Zitti B, Lecce M, Milito ND, Stabile H, Fionda C, et al. CD155: a multi-functional molecule in tumor progression. Int J Mol Sci. 2020;21(3):922.","journal-title":"Int J Mol Sci"},{"key":"2826_CR75","doi-asserted-by":"publisher","first-page":"215830","DOI":"10.1016\/j.canlet.2022.215830","volume":"545","author":"M Zhan","year":"2022","unstructured":"Zhan M, Zhang Z, Zhao X, Zhang Y, Liu T, Lu L, et al. CD155 in tumor progression and targeted therapy. Cancer Lett. 2022;545:215830.","journal-title":"Cancer Lett"},{"key":"2826_CR76","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/1471-2407-4-73","volume":"4","author":"KE Sloan","year":"2004","unstructured":"Sloan KE, Eustace BK, Stewart JK, Zehetmeier C, Torella C, Simeone M, et al. CD155\/PVR plays a key role in cell motility during tumor cell invasion and migration. BMC Cancer. 2004;4:73.","journal-title":"BMC Cancer"},{"issue":"23","key":"2826_CR77","doi-asserted-by":"publisher","first-page":"10930","DOI":"10.1158\/0008-5472.CAN-05-1890","volume":"65","author":"KE Sloan","year":"2005","unstructured":"Sloan KE, Stewart JK, Treloar AF, Matthews RT, Jay DG. CD155\/PVR enhances glioma cell dispersal by regulating adhesion signaling and focal adhesion dynamics. Cancer Res. 2005;65(23):10930\u20137.","journal-title":"Cancer Res"},{"issue":"2","key":"2826_CR78","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s11060-010-0323-5","volume":"102","author":"BM Enloe","year":"2011","unstructured":"Enloe BM, Jay DG. Inhibition of Necl-5 (CD155\/PVR) reduces glioblastoma dispersal and decreases MMP-2 expression and activity. J Neurooncol. 2011;102(2):225\u201335.","journal-title":"J Neurooncol"},{"issue":"3","key":"2826_CR79","doi-asserted-by":"publisher","first-page":"200","DOI":"10.3390\/ph14030200","volume":"14","author":"J Yeo","year":"2021","unstructured":"Yeo J, Ko M, Lee DH, Park Y, Jin HS. TIGIT\/CD226 axis regulates anti-tumor immunity. Pharmaceuticals (Basel). 2021;14(3):200.","journal-title":"Pharmaceuticals (Basel)"},{"key":"2826_CR80","doi-asserted-by":"crossref","unstructured":"Turaga RV, Zima SRT, Peterson EP, Erbe AK, Forsberg MH, Capitini CM, et al. Analysis of phenotypic and molecular variability of memory-like NK cells for cancer adoptive cell therapy screening. Cancers (Basel). 2025;17(14):2288.","DOI":"10.3390\/cancers17142288"},{"issue":"12","key":"2826_CR81","doi-asserted-by":"publisher","first-page":"108353","DOI":"10.1016\/j.isci.2023.108353","volume":"26","author":"KB Lupo","year":"2023","unstructured":"Lupo KB, Torregrosa-Allen S, Elzey BD, Utturkar S, Lanman NA, Cohen-Gadol AA, et al. TIGIT contributes to the regulation of 4-1BB and does not define NK cell dysfunction in glioblastoma. iScience. 2023;26(12):108353.","journal-title":"iScience"},{"issue":"8","key":"2826_CR82","doi-asserted-by":"publisher","first-page":"e1466769","DOI":"10.1080\/2162402X.2018.1466769","volume":"7","author":"AL Hung","year":"2018","unstructured":"Hung AL, Maxwell R, Theodros D, Belcaid Z, Mathios D, Luksik AS, et al. TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM. Oncoimmunology. 2018;7(8):e1466769.","journal-title":"Oncoimmunology"}],"container-title":["Cell Communication and Signaling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12964-026-02826-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-026-02826-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-026-02826-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T05:22:03Z","timestamp":1778563323000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12964-026-02826-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,30]]},"references-count":82,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2826"],"URL":"https:\/\/doi.org\/10.1186\/s12964-026-02826-y","relation":{},"ISSN":["1478-811X"],"issn-type":[{"value":"1478-811X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,30]]},"assertion":[{"value":"29 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the National Medical Ethics Committee of the Republic of Slovenia (approval No. 0120\u2013190\/2018-2711-41). Experiments with human buffy coats were performed in accordance with the approval no. 0120\u2013279\/2017-3.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"289"}}